Drugs News and Research

RSS

Mosaic Therapeutics in-licenses two clinical-stage oncology programs from Astex Pharmaceuticals for development as proprietary combination therapies

Mosaic Therapeutics, Ltd ('Mosaic') a targeted oncology therapeutics company dedicated to resolving cancer's complexity with new combination therapies for patients, today announces the in-licensing of two clinical-stage oncology programs from Astex Pharmaceuticals ('Astex'), a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd.

24 Apr 2025

Metabolic driver of Parkinson’s offers new target for treatment

Researchers have identified a key enzyme driving forms of Parkinson’s, and have shown how blocking it restores normal function in animal and cell models – offering a promising new drug target for the condition.

24 Apr 2025

Scientists uncover why Lyme disease symptoms may linger after treatment

Symptoms that persist long after Lyme disease is treated are not uncommon - a 2022 study found that 14% of patients who were diagnosed and treated early with antibiotic therapy would still develop Post Treatment Lyme Disease (PTLD).

23 Apr 2025

Blocking IL6 pathway may prevent deadly skin ulcers in kidney disease

The global burden of chronic kidney disease (CKD) is rising, with more than 800 million people affected worldwide. Vascular diseases in patients with CKD are unique and grouped as uremic vascular diseases.

23 Apr 2025

Scientists develop promising new drug candidates against coronaviruses

A team at UC San Francisco and Gladstone Institutes has developed new drug candidates that show great promise against the virus that causes COVID-19 and potentially other coronaviruses that could cause future pandemics.

23 Apr 2025

Body image concerns drive interest in GLP-1 weight loss drugs, study finds

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with interest in GLP-1 medications for weight loss. Conversely, body appreciation appears to protect against this interest, especially in the face of potential side effects.

23 Apr 2025

Researchers uncover link between heart attack severity and circadian rhythm

The molecular mechanism behind why heart attacks can vary in severity depending on the time of day has been uncovered by researchers at UTHealth Houston, potentially paving the way for innovative treatments that align with the natural circadian rhythm.

23 Apr 2025

New approach may prevent neurotoxic protein aggregates in ALS

Researchers at Goethe University, Johannes Gutenberg University Mainz and Kiel University discover possible method for preventing protein aggregates – Cluster4Future PROXIDRUGS research project.

23 Apr 2025

Statins linked to better survival in blood cancer patients

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were taking cholesterol-lowering statin medications at the start of their cancer treatment had a 61% lower risk of dying from their cancer compared to similar patients who were not taking statins, according to a study published today in the journal Blood Advances.

23 Apr 2025

Antimalarial drug enhances effect of aminoglycosides in genetic disorders

The antimalarial drug mefloquine could help treat genetic diseases such as cystic fibrosis, Duchenne muscular dystrophy, as well as some cancers.

23 Apr 2025

New approach targets cell surface protein to treat leukemia and solid tumors

In 2021, research led by Ryan Flynn, MD, PhD, and his mentor, Nobel laureate Carolyn Bertozzi, PhD, opened a new chapter in biology, characterizing a new kind of player on the cell surface: glycoRNAs.

23 Apr 2025

Varenicline found to help teens and young adults quit vaping

A new study by investigators from Mass General Brigham showed that teens and young adults who took varenicline-an FDA-approved, twice-daily smoking cessation pill for adults-are more than three times as likely to successfully quit vaping compared to those who received only behavioral counseling. Results are published in JAMA.

23 Apr 2025

DT-109 shows promise in treating atherosclerosis and liver disease

A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis - a primary driver of cardiovascular death worldwide - in large mammals, a study suggests.

23 Apr 2025

UC3M unveils three scientific research projects to combat tuberculosis

Universidad Carlos III de Madrid (UC3M) has presented three scientific research projects contributing to the fight against tuberculosis, the leading cause of death from infectious disease in the world.

23 Apr 2025

DASH diet and salt reduction work together to reduce cardiovascular risk

Reducing dietary sodium and following the DASH diet each lower 10-year risk of atherosclerotic cardiovascular disease, with the greatest benefit when combined. This effect is especially strong for women, Black adults, and those with stage 2 hypertension.

23 Apr 2025